Table 1.
. Demographic and clinical characteristics
| Characteristics | Dexmedetomidine | p-value | |
|---|---|---|---|
| Yes (N=345) | No (N=379) | ||
| Age | 62.9±11.8 | 64.1±11.4 | 0.1694 |
| Gender(F) | 92(26.7) | 108(28.5) | 0.5827 |
| Race (White) | 118(34.2) | 118(31.1) | 0.3794 |
| BMI | 29.4±6.1 | 29.8±7.0 | 0.4665 |
| Hemoglobin (g/dl) | 14.9±2.8 | 15.1±3.1 | 0.5322 |
| Past medical history | |||
| Smoking | 185(53.6) | 208(54.9) | 0.7345 |
| Current Smoking | 70(20.3) | 77(20.3) | 0.9929 |
| Chronic lung disease | 48(13.9) | 57(15.0) | 0.6380 |
| Cerebrovascular Disease | 57(16.5) | 69(18.2) | 0.8701 |
| Peripheral Vascular Disease | 45(13.0) | 51(13.5) | 0.8701 |
| Family History CAD | 65(18.8) | 103(27.2) | 0.0080 |
| Diabetes | 129(37.4) | 113(29.8) | 0.031 |
| Hypertension | 271(78.6) | 289(76.3) | 0.4611 |
| Hypercholesterolemia | 241(69.9) | 304(80.2) | 0.0013 |
| Dyslipidemia | 233(67.5) | 158(41.7) | <0.0001 |
| History of Renal Failure | 17(4.9) | 8(2.1) | 0.0383 |
| Dialysis | 12(3.5) | 7(1.9) | 0.1706 |
| Pre-op Last Creatinine Level | 1.23±1.1 | 1.14±0.68 | 0.1982 |
| Pre-op MI | 121(35.1) | 167(44.1) | 0.0136 |
| CHF | 104(30.1) | 27(7.1) | <0.0001 |
| EF% | 49.7 ±13.3 | 51.9 ±13.0 | 0.0219 |
| Preoperative Medication | |||
| ACEi | 165(47.8) | 220(58.1) | 0.0059 |
| Beta Blockers | 242(70.10) | 255(67.30) | 0.4073 |
| ADP Inhibitors | 19(5.5) | 45(11.9) | 0.0026 |
| Nitrates | 11(3.2) | 13(3. 4) | 0.8561 |
| Anti platelets | 6(1.7) | 4(1.1) | 0.4314 |
| Anticoagulants | 65(18.8) | 92(24.3) | 0.0024 |
| Coumadin | 26(7.5) | 26(6.9) | 0.7251 |
| Inotropes | 2(0.6) | 4(1.1) | 0.4810 |
| Aspirin | 270(78.3) | 305(80.7) | 0.4093 |
| Lipid Lowering Medications | 138(40.0) | 252(66.5) | <0.0001 |
| GPIIb/IIIa Inhibitors | 8(2.3) | 24(6.3) | 0.0087 |
| Propensity score | 0.38(0.22) | 0.63(0.22) | P<0.0001 |
Values are n (%) for categorical variables and mean±SD for continuous variables. BMI, Body Mass Index; CAD, Coronary Arterial Disease; Pre-op MI, preoperative myocardial infarction (MI); CHF, Chronic heart failure; EF, ejection fraction; ACEi, angiotensin converting enzyme inhibitors. ADP, Adenosine diphosphate; GPIIb/IIIa Inhibitors, glycoprotein IIb/IIIa inhibitors